BCM
JUNO

Bienville Capital Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Bienville Capital Management’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-9,000
Closed -$470K – 103
2014
Q4 		$470K Buy
+9,000
New +$403K 0.39% 40

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Bienville Capital Management's JUNO Position: Q1 2015 in Review

Bienville Capital Management sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2015, closing a stake of 9,000 shares — an estimated $470K sold.

Bienville Capital Management first reported a position in JUNO in Q4 2014 and held it in 1 quarter. The position peaked at $470K in Q4 2014. 120 funds tracked by Wall St. Rank hold JUNO as of Q1 2015.

  • Bienville Capital Management reported no remaining Juno Therapeutics, Inc. position as of Q1 2015 after selling out during the quarter.
  • Bienville Capital Management sold 9,000 Juno Therapeutics, Inc. shares in Q1 2015, an estimated $470K.
  • Bienville Capital Management first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 1 quarter.
  • Bienville Capital Management's Juno Therapeutics, Inc. position peaked at $470K in Q4 2014.
  • 120 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2015.

Based on Bienville Capital Management's 13F filing for Q1 2015, filed 13 May 2015.